IMAvaxim 80 0.5 mL primary dose, followed by a booster dose 6-36 mth later. Avaxim 160 0.5 mL primary dose, followed by a booster dose 6-12 mth or 6-36 mth later. Can also be administered as a booster dose of hepatitis A vaccine after receiving combined typhoid fever & hepatitis A vaccine 6-36 mth earlier.
Do not administer IV or intradermally. Patients on immunosuppressants (eg, corticosteroids, cytotoxic drugs, radiotherapy) or in a state of immune deficiency (eg, HIV infection). Patients w/ haemophilia or those easily subjected to bruises or bleeding. Liver disease. May not work properly in patients w/ HAV infection at the time of vaccination. Pregnancy.
Fatigue; pain, redness, oedema or induration at inj site; headache, GI disorders (eg, diarrhoea, abdominal pain); muscular or joint pain; nausea, vomiting; loss of appetite; fever. Avaxim 80 Irritability, insomnia.